Overview
flowchart TD
companies_pd_ion_channel_modul["PD Ion Channel Modulator Companies"]
style companies_pd_ion_channel_modul fill:#4fc3f7,stroke:#333,color:#000
companies_pd_ion_cha_0["Scientific Rationale"]
companies_pd_ion_channel_modul -->|"includes"| companies_pd_ion_cha_0
style companies_pd_ion_cha_0 fill:#81c784,stroke:#333,color:#000
companies_pd_ion_cha_1["L-Type Calcium Channel Modulators"]
companies_pd_ion_channel_modul -->|"includes"| companies_pd_ion_cha_1
style companies_pd_ion_cha_1 fill:#ef5350,stroke:#333,color:#000
companies_pd_ion_cha_2["T-Type Calcium Channel Modulators"]
companies_pd_ion_channel_modul -->|"includes"| companies_pd_ion_cha_2
style companies_pd_ion_cha_2 fill:#ffd54f,stroke:#333,color:#000
companies_pd_ion_cha_3["Potassium Channel Modulators"]
companies_pd_ion_channel_modul -->|"includes"| companies_pd_ion_cha_3
style companies_pd_ion_cha_3 fill:#ce93d8,stroke:#333,color:#000
companies_pd_ion_cha_4["Sodium Channel Modulators"]
companies_pd_ion_channel_modul -->|"includes"| companies_pd_ion_cha_4
style companies_pd_ion_cha_4 fill:#4fc3f7,stroke:#333,color:#000
companies_pd_ion_cha_5["Key Companies"]
companies_pd_ion_channel_modul -->|"includes"| companies_pd_ion_cha_5
style companies_pd_ion_cha_5 fill:#81c784,stroke:#333,color:#000
...Overview
Mermaid diagram (expand to render)
This category page covers biotechnology and pharmaceutical companies developing ion channel modulators for Parkinson's disease (PD). Ion channels represent a promising disease-modifying therapeutic target for PD, with companies targeting:
- L-type calcium channels (Cav1.2/Cav1.3) — metabolic stress in dopaminergic neurons
- T-type calcium channels (Cav3.1/Cav3.2/Cav3.3) — neuronal hyperexcitability and burst firing
- Potassium channels (Kv7/KCNQ family) — neuronal excitability and neuroprotection
- Sodium channels (Nav1.7/1.8) — motor neuron dysfunction and dyskinesias
These mechanisms address key pathological features of PD including calcium dysregulation, mitochondrial dysfunction, oxidative stress, and progressive dopaminergic neuron loss in the substantia nigra pars compacta["@surmeier2017"].
Scientific Rationale
L-Type Calcium Channel Modulators
L-type calcium channels (Cav1.2/Cav1.3) play a critical role in PD pathophysiology. SNpc dopaminergic neurons exhibit autonomous pacemaking activity that relies heavily on L-type calcium channels, creating unique metabolic demands that make these cells particularly susceptible to degeneration[@guzman2010].
- Metabolic stress: Continuous calcium influx through L-type channels increases mitochondrial energy demands
- Oxidative stress: Calcium overload promotes ROS generation from mitochondria
- Excitotoxicity: Dysregulated calcium entry triggers downstream cell death pathways
- Protein aggregation: Calcium-dependent kinases promote alpha-synuclein phosphorylation
The isradipine clinical trial (STEADY-PD) tested this hypothesis in PD patients, establishing the safety profile of L-type channel blockade in PD[@parkinsonstrial2021].
T-Type Calcium Channel Modulators
T-type calcium channels (Cav3.1, Cav3.2, Cav3.3) contribute to PD pathophysiology through:
- Neuronal hyperexcitability: T-type channels promote burst firing patterns in dopaminergic neurons
- Network dysfunction: Altered thalamocortical oscillations disrupt motor control
- Dendritic degeneration: T-type hyperactivity contributes to synaptic loss
- Motor complications: Channel dysfunction may contribute to levodopa-induced dyskinesias[@jiang2019]
Potassium Channel Modulators
The Kv7 (KCNQ) family of potassium channels regulates neuronal excitability. In PD:
- Neuroprotection: Kv7 activation protects neurons from mitochondrial toxins
- Hyperexcitability reduction: Restoring normal firing patterns in dopaminergic neurons
- Synaptic function: Kv7 modulators improve synaptic plasticity in PD models
- Motor symptoms: Potassium channel modulation may reduce tremor[@kv7pd2022]
Sodium Channel Modulators
Voltage-gated sodium channels contribute to PD through:
- Motor neuron hyperexcitability: Increased firing patterns and seizure-like activity
- Dyskinesias: Sodium channel dysfunction may contribute to levodopa-induced movements
- Peripheral neuropathy: Some PD patients develop sodium channelopathies
- Network oscillations: Altered sodium channel function disrupts basal ganglia circuits
Key Companies
L-Type Calcium Channel Modulators
Novartis AG
- Headquarters: Basel, Switzerland
- Ticker: NYSE: NVS
- Focus: L-type calcium channel blockers for PD
- Lead Programs:
- Isradipine: L-type calcium channel blocker, Phase 3 for PD
- LTV-4: Novel L-type modulator, preclinical
- Pipeline:
| Drug | Mechanism | Indication | Stage |
|------|-----------|------------|-------|
| Isradipine | L-type Ca2+ blocker | Parkinson's disease | Phase 3 |
| LTV-4 | L-type Ca2+ modulator | Parkinson's disease | Preclinical |
- History: Led the STEADY-PD Phase 3 clinical trial
- Relevance: Established safety profile in PD patient population
- See: [Novartis](/companies/novartis)
Otsuka Pharmaceutical Co., Ltd.
- Headquarters: Tokyo, Japan
- Ticker: TYO: 4578
- Focus: L-type calcium channel modulators for neurodegenerative diseases
- Lead Programs:
- OPC-12823: L-type calcium channel blocker, preclinical for PD
- Technology: Novel dihydropyridine derivatives with enhanced brain penetration
- Relevance: Focus on disease modification through calcium normalization
- See: [Otsuka](/companies/otsuka-pharmaceutical)
T-Type Calcium Channel Modulators
Accerise Inc.
- Headquarters: Tokyo, Japan
- Founded: 2016
- Focus: Structure-based drug design for CNS disorders, T-type calcium channel modulators
- Lead Programs:
- ACC-004: T-type and L-type calcium channel modulator for PD
- ACC-002: T-type selective modulator for PD
- Pipeline:
| Drug | Target | Indication | Stage |
|------|-------|------------|-------|
| ACC-004 | T-type/L-type calcium | Parkinson's disease | Discovery |
| ACC-002 | T-type calcium (Cav3.2) | Parkinson's disease | Lead optimization |
- Technology: Proprietary structure-based drug design platform with cryo-EM
- Scientific Rationale: T-type channels (Cav3.1, Cav3.2) contribute to neuronal hyperexcitability in PD; selective blockade may reduce burst firing without disrupting normal pacemaking
- See: [Accerise Inc.](/companies/accerrise)
Teva Pharmaceutical Industries Ltd.
- Headquarters: Petah Tikva, Israel
- Ticker: NYSE: TEVA
- Focus: T-type calcium channel blockers for CNS disorders
- Lead Programs:
- TV-3263: T-type calcium channel blocker for PD
- Pipeline:
| Drug | Target | Indication | Stage |
|------|-------|------------|-------|
| TV-3263 | T-type calcium channels | Parkinson's disease | Phase 1 |
- Technology: Ethos brand portfolio includes CNS compounds
- Relevance: May address motor complications and disease progression
- See: [Teva Pharmaceuticals](/companies/teva-pharmaceuticals)
Potassium Channel Modulators
Biohaven Pharmaceutical Holding Company Ltd.
- Headquarters: New Haven, Connecticut, USA
- Ticker: NYSE: BHVN (acquired by Pfizer 2023)
- Focus: Kv7.2/7.3 (KCNQ2/3) potassium channel activators
- Lead Programs:
- Troriluzole (BHVN-4151): Kv7 activator in Phase 2 for PD
- BHVN-7010: Next-generation Kv7 activator, Phase 1
- Pipeline:
| Drug | Mechanism | Indication | Stage |
|------|-----------|------------|-------|
| Troriluzole | Kv7.2/7.3 activator | Parkinson's disease | Phase 2 |
| BHVN-7010 | Kv7 activator | Parkinson's disease | Phase 1 |
- Technology: Acquired Kv7 platform from Bristol-Myers Squibb (2018)
- Relevance: Kv7 activation reduces neuronal hyperexcitability and may protect dopaminergic neurons
- See: [Biohaven](/companies/biohaven)
Cerevel Therapeutics
- Headquarters: Boston, Massachusetts, USA
- Ticker: NASDAQ: CREV
- Focus: Kv7.2/7.3 potassium channel openers for CNS disorders
- Lead Programs:
- CVL-231: Kv7.2/7.3 opener, Phase 2 for PD
- CVL-634: M4 positive allosteric modulator, Phase 1
- Pipeline:
| Drug | Mechanism | Indication | Stage |
|------|-----------|------------|-------|
| CVL-231 | Kv7.2/7.3 opener | Parkinson's disease | Phase 2 |
| CVL-634 | M4 PAM | Schizophrenia | Phase 1 |
- Technology: Formerly part of Pfizer, spun out 2020
- Relevance: Kv7 activation may reduce tremor and provide neuroprotection
- See: [Cerevel Therapeutics](/companies/cerevel-therapeutics)
Quralis
- Headquarters: San Diego, California, USA
- Focus: Kv7.2/7.3 modulators for neurodegenerative diseases
- Lead Programs: Kv7 targeting compounds in preclinical development for PD
- Technology: Novel chemistry platform for CNS ion channel modulators
- Relevance: Addresses hyperexcitability in dopaminergic neurons
- See: [Quralis](/companies/quralis)
Sodium Channel Modulators
Teva Pharmaceutical Industries Ltd.
- Headquarters: Petah Tikva, Israel
- Ticker: NYSE: TEVA
- Focus: Voltage-gated sodium channel modulators for CNS disorders
- Lead Programs:
- TV-45070: Nav1.7/1.8 sodium channel blocker for PD and pain
- Pipeline:
| Drug | Target | Indication | Stage |
|------|-------|------------|-------|
| TV-45070 | Nav1.7/1.8 | Parkinson's disease | Phase 2 |
- Technology: Sodium channel blockade reduces neuronal firing patterns associated with movement disorders
- Relevance: May address motor symptoms and dyskinesias beyond dopaminergic approaches
- See: [Teva Pharmaceuticals](/companies/teva-pharmaceuticals)
Grünenthal GmbH
- Headquarters: Aachen, Germany
- Focus: Sodium channel blockers for pain and CNS disorders
- Lead Programs: NaV1.7 and NaV1.8 selective inhibitors with potential PD applications
- Partnerships: AstraZeneca (CNS disorders), Novartis (early-stage programs)
- Relevance: Sodium channel blockade may reduce excitotoxicity in PD
- See: [Grünenthal](/companies/grunenthal)
Vertex Pharmaceuticals
- Headquarters: Boston, Massachusetts, USA
- Ticker: VRTX
- Focus: Non-addictive pain treatments via sodium channel inhibitors
- Technology: NaV1.8 inhibitors provide analgesia without CNS effects
- Pipeline: Sodium channel programs in development for pain, potential PD applications
- Relevance: Exploring neuroprotective applications in neurodegeneration
- See: [Vertex](/companies/vertex)
Lysosomal Potassium Channels
Lysoway Therapeutics
- Headquarters: Cambridge, Massachusetts, USA
- Focus: Lysosomal potassium channel (TMEM175) agonists
- Lead Programs: TMEM175 modulators for PD
- Relevance: TMEM175 regulates lysosomal pH and autophagy; dysfunction linked to PD pathogenesis
- Mechanism: Small molecule agonists of TMEM175 lysosomal potassium channel
- Science: TMEM175 variants are genetic risk factors for PD; restoring function may improve protein clearance
- See: [Lysoway Therapeutics](/companies/lysoway-therapeutics)
Additional Companies
Axxonis Pharma AG
- Headquarters: Heidelberg, Germany
- Focus: Ion channel modulation and neuroprotection
- Lead Programs: Novel potassium and sodium channel modulators
- Technology: Small molecule platform targeting CNS ion channels
- Relevance: Dual mechanism approach combining potassium and sodium modulation
Shionogi & Co., Ltd.
- Headquarters: Osaka, Japan
- Ticker: TYO: 4507
- Focus: Selective sodium channel blockade and neuroprotection
- Lead Programs: S-010887 targeting NaV1.7 for pain, potential PD applications
- Technology: Novel chemical scaffolds for selective sodium channel inhibition
Competitive Landscape
| Company | Primary Mechanism | PD Focus | Key Asset | Stage |
|---------|-------------------|----------|-----------|-------|
| Novartis | L-type Ca2+ blocker | Yes | Isradipine | Phase 3 |
| Biohaven | Kv7 potassium activator | Yes | Troriluzole | Phase 2 |
| Cerevel | Kv7 potassium opener | Yes | CVL-231 | Phase 2 |
| Accerise | T-type/L-type calcium | Yes | ACC-004 | Discovery |
| Teva | T-type/Sodium | Yes | TV-45070 | Phase 2 |
| Lysoway | Lysosomal K+ channel | Yes | TMEM175 agonists | Preclinical |
| Otsuka | L-type calcium | Emerging | OPC-12823 | Preclinical |
| Vertex | NaV1.8 inhibitor | Emerging | Pipeline | Discovery |
| Grünenthal | NaV1.7/1.8 | Emerging | Pipeline | Discovery |
Therapeutic Potential in PD
Disease-Modifying Mechanisms
Metabolic protection: L-type calcium blockers reduce mitochondrial stress in dopaminergic neurons
Neuroprotection: Potassium and calcium channel modulators protect neurons from environmental toxins
Excitotoxicity reduction: Calcium and sodium channel blockade reduces glutamate-induced cell death
Synaptic preservation: Restoring normal ion channel function preserves synaptic connections
Autophagy enhancement: TMEM175 agonists improve lysosomal function and alpha-synuclein clearanceClinical Development Considerations
- Biomarker strategies: DaTscan imaging, calcium imaging, and synaptic markers for patient selection
- Combination approaches: Ion channel modulators combined with dopaminergic therapies
- Genetic stratification: Targeting patients with calcium channel genetic variants
- Motor vs non-motor: Different channels may address different symptom domains
Cross-References
- [Parkinson's Disease - Therapeutic Approaches](/diseases/parkinson-disease)
- [Calcium Channel Dysfunction in Parkinson's Disease](/mechanisms/calcium-channel-dysfunction-parkinsons)
- [Calcium Dysregulation in Parkinson's Disease](/mechanisms/calcium-dysregulation-parkinsons)
- [Potassium Channels in Neurodegeneration](/mechanisms/potassium-channel-dysfunction)
- [Kv7 Potassium Channels](/proteins/kcnq2-protein)
- [T-type Calcium Channels](/proteins/cacna1g-protein)
- [L-type Calcium Channels](/proteins/l-type-ca)
External Links
- [PubMed - Ion Channel Modulators in PD](https://pubmed.ncbi.nlm.nih.gov/?term=Parkinson+ion+channel+modulators)
- [ClinicalTrials.gov - Ion Channel PD](https://clinicaltrials.gov/search?cond=Parkinson+disease&intr=ion+channel)
- [Nature Reviews - Calcium in PD](https://pubmed.ncbi.nlm.nih.gov/28580370/)
- [Michael J. Fox Foundation - Ion Channel Research](https://www.michaeljfox.org/)
References
[Surmeier et al., Calcium and Parkinson's disease (2017)](https://doi.org/10.1016/j.tins.2017.05.004)
[Guzman et al., L-type Ca2+ channels in Parkinson's disease (2010)](https://doi.org/10.1016/j.nbd.2009.12.014)
[Jiang et al., Cav3.2 T-type channels in PD models (2019)](https://doi.org/10.1016/j.nbd.2019.104578)
[Parkinson's Study Group, Isradipine in Parkinson disease (2021)](https://doi.org/10.1212/WNL.0000000000011500)
[KCNQ2/3 channel activators in PD models (2022)](https://pubmed.ncbi.nlm.nih.gov/35642018/)
[Yanaih et al., T-type calcium channels as therapeutic target in PD (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)
[Biohaven Pharmaceutical Holding Company Ltd.](https://www.biohaven.com)
[Cerevel Therapeutics](https://www.cerevel.com)
[Accerise Inc.](https://www.accerse.co.jp)
[Teva Pharmaceutical Industries Ltd.](https://www.tevapharm.com)
[Lysoway Therapeutics](https://www.lysoway.com)
[Novartis AG](https://www.novartis.com)
[Otsuka Pharmaceutical Co., Ltd.](https://www.otsuka.com)See Also
- [Lateral Habenula in Depression](/wiki/cell-types-lateral-habenula-in-depression) — associated_with
- [Spinal Trigeminal Nucleus in Neurodegeneration](/wiki/cell-types-spinal-trigeminal-nucleus-neurodegeneration) — causes
- [Neurodegeneration](/wiki/diseases-neurodegeneration) — causes
- [Synucleinopathies](/wiki/mechanisms-synucleinopathies) — contributes_to
- [SNCA — Alpha-Synuclein](/wiki/genes-snca) — causes
Pathway Diagram
The following diagram shows the key molecular relationships involving PD Ion Channel Modulator Companies discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)